ADIPOQ and chronic obstructive pulmonary disease: In addition, levels of circulating adiponectin were affected in patients with certain comorbidities compared to patients without these comorbidities, namely, hypertension (10.6 μg/mL vs. 7.6 μg/mL), diabetes (7.2 μg/mL vs. 9.4 μg/mL), and chronic obstructive pulmonary disease (COPD) (14.8 μg/mL vs. 8.9 μg/mL) (Table 2).